Thornburg Investment Management Inc. Purchases Shares of 45,404 Eli Lilly and Company $LLY

Thornburg Investment Management Inc. bought a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, HoldingsChannel reports. The firm bought 45,404 shares of the company’s stock, valued at approximately $48,795,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its stake in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in Eli Lilly and Company during the second quarter worth about $356,000. Finally, Nebula Research & Development LLC purchased a new stake in Eli Lilly and Company during the second quarter worth about $749,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,130.12 on Tuesday. The company has a 50 day moving average of $1,002.35 and a 200 day moving average of $1,016.51. The stock has a market cap of $1.06 trillion, a P/E ratio of 40.15, a P/E/G ratio of 1.24 and a beta of 0.53. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,182.73. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Insider Monkey highlighted Eli Lilly as one of billionaire Ken Fisher’s top high-growth stock picks, a vote of confidence that may reinforce the market’s view that LLY remains a high-quality growth name. Billionaire Ken Fisher’s Top 5 High-Growth Stock Picks
• Positive Sentiment: Shares could benefit from a PRNewswire update showing Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death in a Phase 3 CLL/SLL trial, suggesting Lilly’s pipeline has catalysts beyond obesity drugs. Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk…
• Positive Sentiment: A Yahoo Finance article noted that Lilly’s newer JAK2 inhibitor data supports the idea that the company has broader growth drivers and possible upside beyond its obesity franchise. Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside
• Neutral Sentiment: Multiple articles repeated the same bullish thesis that investors still like Eli Lilly for its strong growth, but some are questioning whether the stock’s valuation leaves less room for near-term upside. Should You Buy Eli Lilly Stock Now or Wait for a Dip?
• Negative Sentiment: That same valuation concern could weigh on the stock, since analysts and commentators continue to describe LLY as expensive even after its strong operating performance. Should You Buy Eli Lilly Stock Now or Wait for a Dip?

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.